Tumour necrosis factor rheumatoid arthritis

Kang, C. P. et al., The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis, Rheumatology (Oxford), 44, 547, 2005. [Pg.93]

Barrera, P., Joosten, L. A., den Broeder, A. A., van de Putte, L. B., van Riel, P. L., and van den Berg, W. B. (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 60, 660-669. [Pg.436]

Cuchacovich, M., Ferreira, L., Aliste, M., et al. (2004) Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology. 33, 228-232. [Pg.436]

Waldron-Lynch, F., Adams, C., Amos, C., et al. (2001) Tumour necrosis factor 5 promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogeneticaUy defined multiplex RA families. Genes and Immunity. 2, 82-87. [Pg.436]

Roberts L, McColl GJ. Tumour necrosis factor inhibitors risks and benefits in patients with rheumatoid arthritis. Intern MedJ. 2004 34 687-693. [Pg.235]

Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S. et al. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. [Pg.409]

Main R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate a randomised phase III trial. ATTRACT Study Group. Lancet 1999 354(9194) 1932-9. [Pg.1751]

Seitz M, Wirthmuller U, Moller B, Villiger PM (2007) The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxf) 46 93-96... [Pg.657]

Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA et al (2010) Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis systematic review and meta-analysis. Ann Rheum Dis 69 1022-1028... [Pg.657]

Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD et al (2008) Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 17 3532-3538... [Pg.658]

Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG et al (2010) Investigation of rheumatoid arthritis susceptibility genes identifies association ofAFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 69 1029-1035... [Pg.659]

Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I et al (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62 526-529... [Pg.659]

Hyrich KL, Silman AJ, Watson KD, Symmons DPM (2004) Anti-tumour necrosis factor a therapy in rheumatoid arthritis an update on safety. Ann Rheum Dis, 63 1538-1543. [Pg.283]

Sorensen J Andersen LS (2005) The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis a budget impact analysis. Pharmacoeconomics, 23 289-298. [Pg.313]

Cytokines are chemicals released by damaged cells and cells involved in inflammation and repair. Drugs have been developed against two of them, tumour necrosis factor a (TNF-a) and interleukin 1 (IL-1). These two cytokines are released from macrophages and together they are key players in the inflammatory response. Levels of both are raised in rheumatoid arthritis and other autoimmune diseases. [Pg.122]

Buchan, G., Barrett, K., Turner, M., Chantry, D., Maini, R. N., and Feldmann, M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis Prolonged production of IL-1 alpha. Clin. Exp. Immunol 73, 449-455 (1988). [Pg.58]

Moreland LW. Drugs that block tumour necrosis factor experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004 22 39-53. [Pg.138]

Elliott M J, Maini R N, Feldmann M, et al. (1994). Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 344 1125-1127. [Pg.1193]

BIO. Brennan, F. M., Brovme, K. A., Green, P. A., Jaspar, J. M., Maini, R. N., and Feldmann, M., Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br. J. Rheumatol. 36, 643-650 (1997). [Pg.75]

C2. Catrina, A. I., Lampa, J., Ernestam, S., af Klint, E., Bratt, J., Klareskog, L., and Uhgren, A. K., Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41, 484-489 (2002). [Pg.75]

Gilaberte Y. Coscojuela C, Vazquez C et ak Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors adminisrered for rheumatoid arthritis. Br J Dermatol 2007 156(2) 368-371. [Pg.75]

Salk, A., Stobaugh, D.J., Deepak, R, and Ehrenpreis, E.D. 2013. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-a inhibitors an analysis of reports to the US FDA adverse event reporting system. Drug Sqf, 36 329-334. [Pg.240]

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DPM. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor... [Pg.800]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...